STRATA Skin Sciences reported a challenging third quarter with revenues decreasing by 20% year-over-year, largely due to international market pressures, while domestic recurring revenues demonstrate resilience and growth.

• Total revenue for Q3 2025 was $6.9 million, a decline of 20% compared to Q3 2024, primarily impacted by international trade uncertainties.
• U.S. recurring revenue from XTRAC increased by 2.8%, signaling stability within domestic operations.
• The expanded CPT codes for XTRAC treatments, effective January 2027, offer potential access to over 30 million patients, significantly enlarging the company’s market opportunity.
• The Elevate360 program has driven an average clinic growth rate of 7% year-over-year and improved gross billings per device by 8.5% compared to last year.
• STRATA is pursuing legal action against LaserOptik, anticipating significant damages that could bolster revenue from previously misled clinics.